{"entity":{"type":"insider","cik":"0001356256","url":"/insider/0001356256","json_url":"/insider/0001356256.json","name":"Myers Scott Dunseth","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":13,"n_filings":12,"first":"2006-05-26","last":"2025-08-25","span_basis":"filed_date"},"name_variants":[{"name":"Myers Scott Dunseth","source":"filing","n_filings":12,"first_seen":"2006-05-26","last_seen":"2025-08-25"}],"transactions":[{"id":4984361,"accession":"0001029142-25-000120","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001029142-25-000120","line_url":"/filing/0001029142-25-000120#line-1","is_derivative":false,"issuer_cik":"0001029142","issuer_name":"DYNAVAX TECHNOLOGIES CORP","issuer_ticker":"DVAX","issuer_name_source":null,"issuer_url":"/issuer/0001029142","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":3800.0,"shares_display":"3,800","price_per_share":10.82,"price_display":"10.82","price_state":"stated","total_value":41116.0,"total_display":"41,116.00","total_whole":"41,116","shares_owned_after":35004.0,"shares_owned_after_display":"35,004","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-22","filed_date":"2025-08-25","scope":"insider"},{"id":4963612,"accession":"0001725160-25-000094","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001725160-25-000094","line_url":"/filing/0001725160-25-000094#line-1","is_derivative":false,"issuer_cik":"0001356256","issuer_name":"Zentalis Pharmaceuticals, Inc.","issuer_ticker":"ZNTL","issuer_name_source":null,"issuer_url":"/issuer/0001356256","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Director","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":21000.0,"shares_display":"21,000","price_per_share":1.3987,"price_display":"1.40","price_state":"stated","total_value":29372.7,"total_display":"29,372.70","total_whole":"29,373","shares_owned_after":281192.0,"shares_owned_after_display":"281,192","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-04-30","filed_date":"2025-04-30","scope":"insider"},{"id":8724113,"accession":"0000950170-23-012595","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-012595","line_url":"/filing/0000950170-23-012595#line-1","is_derivative":false,"issuer_cik":"0001356256","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001356256","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":4000.0,"shares_display":"4,000","price_per_share":25.3697,"price_display":"25.37","price_state":"stated","total_value":101478.8,"total_display":"101,478.80","total_whole":"101,479","shares_owned_after":259500.0,"shares_owned_after_display":"259,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-04-12","filed_date":"2023-04-12","scope":"insider"},{"id":8281778,"accession":"0000950170-23-007570","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-23-007570","line_url":"/filing/0000950170-23-007570#line-1","is_derivative":false,"issuer_cik":"0001356256","issuer_name":"Viridian Therapeutics, Inc.\\DE","issuer_ticker":"VRDN","issuer_name_source":null,"issuer_url":"/issuer/0001356256","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Director, Officer (Chief Executive Officer)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Chief Executive Officer","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5500.0,"shares_display":"5,500","price_per_share":29.1499,"price_display":"29.15","price_state":"stated","total_value":160324.45,"total_display":"160,324.45","total_whole":"160,324","shares_owned_after":255500.0,"shares_owned_after_display":"255,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2023-03-13","filed_date":"2023-03-13","scope":"insider"},{"id":4267791,"accession":"0001209191-17-048790","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-048790","line_url":"/filing/0001209191-17-048790#line-1","is_derivative":false,"issuer_cik":"0001356256","issuer_name":"Cascadian Therapeutics, Inc.","issuer_ticker":"CASC","issuer_name_source":null,"issuer_url":"/issuer/0001356256","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5500.0,"shares_display":"5,500","price_per_share":3.735,"price_display":"3.74","price_state":"stated","total_value":20542.5,"total_display":"20,542.50","total_whole":"20,543","shares_owned_after":49716.0,"shares_owned_after_display":"49,716","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-08-11","filed_date":"2017-08-14","scope":"insider"},{"id":4322946,"accession":"0001209191-17-032832","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-032832","line_url":"/filing/0001209191-17-032832#line-1","is_derivative":false,"issuer_cik":"0001356256","issuer_name":"Cascadian Therapeutics, Inc.","issuer_ticker":"CASC","issuer_name_source":null,"issuer_url":"/issuer/0001356256","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2800.0,"shares_display":"2,800","price_per_share":3.997,"price_display":"4.00","price_state":"stated","total_value":11191.6,"total_display":"11,191.60","total_whole":"11,192","shares_owned_after":44216.0,"shares_owned_after_display":"44,216","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-05-12","filed_date":"2017-05-16","scope":"insider"},{"id":4739040,"accession":"0001209191-17-025174","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-025174","line_url":"/filing/0001209191-17-025174#line-1","is_derivative":false,"issuer_cik":"0001356256","issuer_name":"Cascadian Therapeutics, Inc.","issuer_ticker":"CASC","issuer_name_source":null,"issuer_url":"/issuer/0001356256","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":2000.0,"shares_display":"2,000","price_per_share":4.1143,"price_display":"4.11","price_state":"stated","total_value":8228.6,"total_display":"8,228.60","total_whole":"8,229","shares_owned_after":41416.0,"shares_owned_after_display":"41,416","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-31","filed_date":"2017-04-04","scope":"insider"},{"id":4414046,"accession":"0001209191-17-022141","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-022141","line_url":"/filing/0001209191-17-022141#line-1","is_derivative":false,"issuer_cik":"0001356256","issuer_name":"Cascadian Therapeutics, Inc.","issuer_ticker":"CASC","issuer_name_source":null,"issuer_url":"/issuer/0001356256","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":1000.0,"shares_display":"1,000","price_per_share":3.9271,"price_display":"3.93","price_state":"stated","total_value":3927.1,"total_display":"3,927.10","total_whole":"3,927","shares_owned_after":39416.0,"shares_owned_after_display":"39,416","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-20","filed_date":"2017-03-21","scope":"insider"},{"id":4706309,"accession":"0001209191-17-006410","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-17-006410","line_url":"/filing/0001209191-17-006410#line-1","is_derivative":false,"issuer_cik":"0001356256","issuer_name":"Cascadian Therapeutics, Inc.","issuer_ticker":"CASC","issuer_name_source":null,"issuer_url":"/issuer/0001356256","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":20500.0,"shares_display":"20,500","price_per_share":3.758,"price_display":"3.76","price_state":"stated","total_value":77039.0,"total_display":"77,039.00","total_whole":"77,039","shares_owned_after":38416.0,"shares_owned_after_display":"38,416","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-01-27","filed_date":"2017-01-31","scope":"insider"},{"id":3211905,"accession":"0001209191-16-137799","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-137799","line_url":"/filing/0001209191-16-137799#line-1","is_derivative":false,"issuer_cik":"0001356256","issuer_name":"Cascadian Therapeutics, Inc.","issuer_ticker":"CASC","issuer_name_source":null,"issuer_url":"/issuer/0001356256","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":45000.0,"shares_display":"45,000","price_per_share":1.1499,"price_display":"1.15","price_state":"stated","total_value":51745.5,"total_display":"51,745.50","total_whole":"51,746","shares_owned_after":107500.0,"shares_owned_after_display":"107,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-08-17","filed_date":"2016-08-18","scope":"insider"},{"id":2738729,"accession":"0001209191-16-129931","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-16-129931","line_url":"/filing/0001209191-16-129931#line-1","is_derivative":false,"issuer_cik":"0001356256","issuer_name":"Cascadian Therapeutics, Inc.","issuer_ticker":"CASC","issuer_name_source":null,"issuer_url":"/issuer/0001356256","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Director, Officer (President and CEO)","role_mark":"D","role_mark_label":"Director","role_mark_generic":"Director","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"President and CEO","security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":62500.0,"shares_display":"62,500","price_per_share":0.8,"price_display":"0.80","price_state":"stated","total_value":50000.0,"total_display":"50,000.00","total_whole":"50,000","shares_owned_after":62500.0,"shares_owned_after_display":"62,500","ownership_form":"D","is_10b5_1":null,"transaction_date":"2016-06-28","filed_date":"2016-06-28","scope":"insider"},{"id":3804048,"accession":"0001005477-06-002816","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001005477-06-002816","line_url":"/filing/0001005477-06-002816#line-2","is_derivative":false,"issuer_cik":"0001066833","issuer_name":"DOV PHARMACEUTICAL INC","issuer_ticker":"DOVP","issuer_name_source":null,"issuer_url":"/issuer/0001066833","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":2.69,"price_display":"2.69","price_state":"stated","total_value":13450.0,"total_display":"13,450.00","total_whole":"13,450","shares_owned_after":10000.0,"shares_owned_after_display":"10,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-05-25","filed_date":"2006-05-26","scope":"insider"},{"id":3804046,"accession":"0001005477-06-002816","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001005477-06-002816","line_url":"/filing/0001005477-06-002816#line-1","is_derivative":false,"issuer_cik":"0001066833","issuer_name":"DOV PHARMACEUTICAL INC","issuer_ticker":"DOVP","issuer_name_source":null,"issuer_url":"/issuer/0001066833","owner_cik":"0001356256","owner_name":"Myers Scott Dunseth","owner_display_name":"Myers Scott Dunseth","owner_url":"/insider/0001356256","role":"Officer (Senior Vice President)","role_mark":"O","role_mark_label":"Officer (Senior Vice President)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"Senior Vice President","security_title":"Common Stock, par value $0.0001 per share","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":5000.0,"shares_display":"5,000","price_per_share":2.69,"price_display":"2.69","price_state":"stated","total_value":13450.0,"total_display":"13,450.00","total_whole":"13,450","shares_owned_after":5000.0,"shares_owned_after_display":"5,000","ownership_form":"D","is_10b5_1":null,"transaction_date":"2006-05-24","filed_date":"2006-05-26","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":13,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":13,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":13},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001029142","name":"DYNAVAX TECHNOLOGIES CORP","url":"/issuer/0001029142","role":"Director","n_filings":1,"first_seen":"2025-08-25","last_seen":"2025-08-25"},{"type":"issuer","type_label":"ISSUER","cik":"0001725160","name":"Zentalis Pharmaceuticals, Inc.","url":"/issuer/0001725160","role":"Director","n_filings":1,"first_seen":"2025-04-30","last_seen":"2025-04-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001590750","name":"Viridian Therapeutics, Inc.\\DE","url":"/issuer/0001590750","role":"Director, Officer (Chief Executive Officer)","n_filings":2,"first_seen":"2023-03-13","last_seen":"2023-04-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001412067","name":"Cascadian Therapeutics, Inc.","url":"/issuer/0001412067","role":"Director, Officer (President and CEO)","n_filings":7,"first_seen":"2016-06-28","last_seen":"2017-08-14"},{"type":"issuer","type_label":"ISSUER","cik":"0001066833","name":"DOV PHARMACEUTICAL INC","url":"/issuer/0001066833","role":"Officer (Senior Vice President)","n_filings":1,"first_seen":"2006-05-26","last_seen":"2006-05-26"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001356256","retrieved_at":"2026-08-22T13:43:08+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}